Protein C News and Research

RSS

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

AFFiRiS AG announces results of phase 1 trial with PD01A in Parkinson's

AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology.

18 Jun 2020

Novel SARS-CoV-2 antibody cocktail impeccably mimics human antibody response

By using both humanized mice and convalescent patients, the researchers from the US and Singapore successfully generated non-competing and highly potent monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that could potentially be combined to form antibody cocktails. Their groundbreaking paper is published in the leading research journal Science.

18 Jun 2020

Discovery of key steps in kidney formation could have implications for treating renal diseases

The discovery of how certain key structures in the kidneys are formed could have important implications for treating renal fibrosis (or scarring), a feature of chronic kidney disease (CKD), according to a new study by a researcher at Massachusetts General Hospital.

18 Jun 2020

Cyclosporin study may pave way for treating diseases related to mitochondrial dysfunction

Cyclic peptide molecules of the fungal origin called cyclosporins were discovered in 1970's, and cyclosporin A soon became an important drug due to its immunosuppressive activity.

18 Jun 2020

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

By performing a genome-wide CRISPR screen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), U.S. researchers identified novel proviral genes and pathways, and highlighted host genes that may regulate coronavirus disease (COVID-19) pathogenesis, as well as revealing potential targets for novel treatment approaches. Their findings are currently available on the bioRxiv* preprint server.

18 Jun 2020

Certain patients who receive hospital care for COVID-19 exhibit clear signs of brain injury

Certain patients who receive hospital care for coronavirus infection (COVID-19) exhibit clinical and neurochemical signs of brain injury, a University of Gothenburg study shows. In even moderate COVID-19 cases, finding and measuring a blood-based biomarker for brain damage proved to be possible.

18 Jun 2020

Researchers develop tool to identify proteins associated with drug side effects

A multi-institutional group of researchers led by Harvard Medical School and the Novartis Institutes for BioMedical Research has created an open-source machine learning tool that identifies proteins associated with drug side effects.

18 Jun 2020

Scientists aim to understand the biology of SARS-CoV-2 virus to enable drug development

The University of Huddersfield has awarded funding to a research team that aims to provide a head start in developing drugs that will combat future pandemics.

18 Jun 2020

Impact Biomedical's COVID-19 research published in peer-reviewed scientific journal

SGX-listed Singapore eDevelopment Limited's wholly owned subsidiary Impact Biomedical Inc. announced today that their COVID-19 research with Global Research and Discovery Group Sciences, conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc., was published in the peer-reviewed scientific journal Molecules on June 11, 2020.

18 Jun 2020

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta Group plc, is pleased to announce that collaborative work with the University of Glasgow has shown that Affimer reagents prevent infection.

From Avacta Life Sciences Ltd. 18 Jun 2020

New combination of biomarkers can benefit patients with advanced bladder cancer

In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center.

18 Jun 2020

Study paints clear picture of how a protein that calms brain activity works

As the body goes about its daily business, molecules called neurotransmitters control the level of electrical activity within the brain.

17 Jun 2020

Researchers use cellular nanosponges to soak up SARS-CoV-2

Scientists are working overtime to find an effective treatment for COVID-19, the illness caused by the new coronavirus, SARS-CoV-2.

17 Jun 2020

NJIT researchers develop new efficient method for targeted protein analysis

Researchers at New Jersey Institute of Technology in collaboration with Ohio University and Merck & Co. Inc. recently developed a new efficient method for targeted protein analysis -- one they say could speed up processes for disease testing, drug discovery and vaccine development.

17 Jun 2020

Integrin-binding peptide ATN-161: Potential COVID-19 treatment

Now, a new study by researchers at Tulane University and published on the preprint server bioRxiv* in June 2020 reports the potential role of an integrin inhibitor ATN-161 to prevent ACE2-S protein binding.

17 Jun 2020

ACE2 and pattern recognition receptor genes increase with age

A recent study by researchers in California and published on the preprint server bioRxiv* in June 2020 shows that advancing age is associated with increased expression of pattern recognition receptor (PRR) genes and ACE2 receptors, possibly accounting in part for the increased severity of the disease in older adults.

17 Jun 2020

Protein C News and Research

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

AFFiRiS AG announces results of phase 1 trial with PD01A in Parkinson's

Novel SARS-CoV-2 antibody cocktail impeccably mimics human antibody response

Discovery of key steps in kidney formation could have implications for treating renal diseases

Cyclosporin study may pave way for treating diseases related to mitochondrial dysfunction

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

Certain patients who receive hospital care for COVID-19 exhibit clear signs of brain injury

Researchers develop tool to identify proteins associated with drug side effects

Scientists aim to understand the biology of SARS-CoV-2 virus to enable drug development

Impact Biomedical's COVID-19 research published in peer-reviewed scientific journal

Avacta provides update on Affimer therapy for COVID-19 infection

New combination of biomarkers can benefit patients with advanced bladder cancer

Study paints clear picture of how a protein that calms brain activity works

Researchers use cellular nanosponges to soak up SARS-CoV-2

NJIT researchers develop new efficient method for targeted protein analysis

Integrin-binding peptide ATN-161: Potential COVID-19 treatment

ACE2 and pattern recognition receptor genes increase with age

Iron fortification of bouillon or stock shows potential for tackling iron deficiency

NTU researchers develop a sustainable way to extract high-quality antimicrobial compounds

Nanosponges could attack and neutralize SARS-COV-2 virus

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News